Cancer Research UK logo.
SearchDonate
  • Search

A study of pembrolizumab in advanced melanoma (ADAPTeM)

Overview

Cancer types:

Melanoma, Skin cancer

Status:

Results

Phase:

Phase 2

Details

This study looked at taking tissue samples to check how pembrolizumab was working at certain time points during treatment. The study is for people whose cancer has spread to another part of the body (advanced melanoma).

Recruitment start: 14 July 2016

Recruitment end: 20 July 2017

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr James Larkin

Supported by

Cancer Research UK London Research Institute

Merck Sharp Dohme

The Royal Marsden NHS Foundation Trust

University College London Cancer Institute

Last reviewed: 15 Mar 2024

CRUK internal database number: 12710

Help and support